CMPX 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

CMPX ▲ +22.91% at T+20d

LONG call ✓ call won +22.91% · α vs SPY +17.95% · entry $1.79 → $2.20

Next anchor: T+60d in 5w

Last close $2.03 (close Jun 12) · +13.41% from $1.79 entry

Entry anchored
Apr 27, 07:23 AM ET
via Databento tick

T+1d

+2.79%

call +2.79% · α +3.28%

$1.84

settled 7w ago

T+5d

+8.38%

call +8.38% · α +7.98%

$1.94

settled 6w ago

T+20d

+22.91%

call +22.91% · α +17.95%

$2.20

settled 20d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Compass Therapeutics announced positive Phase 2/3 trial data for tovecimig in biliary tract cancer, showing statistically significant improvements in overall response rate and progression-free survival, though overall survival was not met due to high crossover. The company plans to meet with the FDA for a potential Biologics License Application.

Actionable Insight

Monitor upcoming FDA meeting and potential BLA submission timeline, as the positive PFS data could support accelerated approval despite the OS crossover issue.

Key Facts

Tovecimig combination achieved 17.1% ORR vs 5.3% for paclitaxel alone (p=0.031)
Statistically significant improvement in median PFS: 4.7 months vs 2.6 months (HR=0.44, p<0.0001)
OS endpoint not met due to 54% crossover rate from control arm
Crossover patients showed significantly improved median OS of 12.8 months vs 6.1 months for non-crossover patients
Tovecimig was generally well tolerated with no new safety signals

Financial Impact

Potential for accelerated approval pathway and future commercialization

revenuedilutiondebt

Risk Factors

FDA may require additional data beyond PFS for approval
High crossover rate complicates overall survival interpretation

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

95% bullish (22 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001171843-26-002720
Exhibit: exh_992.htm	0001171843-26-002720
Exhibit: exh_991.htm	0001171843-26-002720
Document: 0001171843-26-002720-index-headers.html	0001171843-26-002720
Document: 0001171843-26-002720-index.html	0001171843-26-002720
Document: 0001171843-26-002720.txt	0001171843-26-002720

8 reports for CMPX

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+20▲ +22.91%Apr 27, 2026

Filters

Reports for CMPX — sortable, filterable
	Type				Now
Jun 11, 2026 3d ago	Institutional Cluster MIXED ★ 4/10	$2.00 awaiting T+5	awaiting T+5	—	$2.03 (+1.50%)
May 21, 2026 24d ago	Press Release BULLISH ★ 7/10	$2.07 $2.22	▲ +7.25%	▲ +5.57%	$2.03 (−1.93%)
May 5, 2026 5w ago	8-K BULLISH ★ 7/10	$1.95 $1.83	▼ −6.15%	▼ −8.14%	$2.03 (+4.10%)
Apr 29, 2026 6w ago	DEFA14A NEUTRAL ★ 4/10	$1.67 $1.95	▲ +16.77%	▲ +13.66%	$2.03 (+21.56%)
Apr 27, 2026 6w ago	8-K BULLISH ★ 7/10	$1.79 $1.94	▲ +8.38%	▲ +7.98%	$2.03 (+13.41%)
Apr 27, 2026 6w ago	Press Release BULLISH ★ 8/10	$1.79 $1.94	▲ +8.38%	▲ +7.98%	$2.03 (+13.41%)
Apr 24, 2026 7w ago	Press Release NEUTRAL ★ 5/10	$1.79 $1.94	▲ +8.38%	▲ +7.98%	$2.03 (+13.41%)
Mar 5, 2026 14w ago	8-K / PRESS-RELEASE MIXED ★ 7/10	$5.53 $5.19	▼ −6.15%	▼ −3.91%	$2.03 (−63.29%)

US Market Status

Market Closed — Opens in 5h 1m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access